An observational study in Hypertension, Dyslipidemia and Type 2 Diabetes Mellitus (T2DM), sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Peking University Third Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 408 studies in Hypertension with a site in China — 125 open to participants now, 147 under way, 12 of them phase 3. Hypertension · China.
Among the 408 studies in Hypertension with a site in China, this one is the 22nd largest by planned enrollment of the 102 observational ones that give a count, is one of 37 that started in 2026, is one of 102 observational ones, reaches primary completion later than 122 of the 146 other live ones, and was the 407th registered.
6,118 studies on the registry are indexed under Hypertension; 914 are open to participants now.
Browse Hypertension studies →125 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China Medical University, China · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 562 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
408 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 23 · Phase 3 50 · Phase 4 76
First in 1998; this study’s year is marked. 37 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 350 across 1,163 observational studies indexed under Hypertension.
Median enrollment 255 across the 306 interventional studies, 1,000 across the 102 observational. Of the 160 that completed or were terminated, 22 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 408 have an industry lead sponsor. The 10 most frequent:
Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 276 are open to participants now.
Peking University Third Hospital has 5 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
45 of the studies in Hypertension with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
Add all 45 to your calendar (.ics) → With an account.
Among the 408 studies in Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, prospective, observational cohort study. Study participants will first be enrolled into the general population main cohort, and some eligible subjects will be invited to participate in a validation study for the consistency of estimated VO₂max. The overall study consists of the establishment of the main cohort and three major research modules: cardiovascular endpoint risk prediction, early warning of exercise-related cardiovascular event risk, and health reminder and behavioral feedback. In addition, a substudy is designed to enroll 300 patients with stable metabolic cardiovascular disease, aiming to verify the consistency between wearable-device-estimated maximal oxygen uptake (VO₂max) and the gold standard of Cardiopulmonary Exercise Testing (CPET), so as to evaluate the applicability and error structure of the device-estimated parameters in clinical populations.
To establish a prospective cardiopulmonary exercise and active health cohort based on wearable devices, systematically integrate continuous dynamic physiological and behavioral data as well as standardized clinical outcome information, and evaluate the application value of wearable-device-derived metrics in dynamic cardiovascular risk assessment and exercise-related risk identification. Specific objectives are as follows:
Recruited from volunteers in the general population or health check-up attendees.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group consists of generally healthy individuals without chronic diseases such as hypertension, dyslipidemia, diabetes mellitus, coronary artery disease, and chronic obstructive pulmonary disease (COPD)
The exposure factors of this group are hypertension, dyslipidemia, diabetes mellitus, coronary artery disease (CAD), heart failure (HF), and chronic obstructive pulmonary disease (COPD). All of these chronic diseases have been diagnosed in the participants.
Major Adverse Cardiovascular Events (MACE)
Cardiovascular endpoint events: defined as major events meeting the criteria for MACE (including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), extended to other clinically significant adverse cardiovascular events such as heart failure hospitalization, unstable angina visit, and revascularization.All events will be adjudicated by at least two cardiologists based on device recordings, medical documentation and self-reported symptoms. Any disagreements will be resolved by a third-party adjudicator.
Time frame: From the date of baseline enrollment until the date of first MACE or censoring, assessed up to 12 months.
Exercise-Related Cardiovascular Events
Definition of Exercise-Related Cardiovascular Events: Cardiovascular symptoms or events closely induced by exercise that occur during exercise or in the post-exercise recovery period, including but not limited to: (1) Myocardial infarction or angina attack; (2) Tachyarrhythmias: ventricular tachycardia, atrial tachycardia, atrial flutter, atrial fibrillation, paroxysmal supraventricular tachycardia occurring during exercise or recovery; (3) Bradyarrhythmias: newly developed sinus arrest, atrioventricular block, left/right bundle branch block; (4) Abnormal exercise blood pressure: systolic blood pressure ≥210 mmHg (male) or ≥190 mmHg (female) during exercise, abrupt blood pressure drop \>10 mmHg with evidence of ischemia during exercise; (5) Syncope, sudden cardiac death, cardiac arrest; (6) Other cardiovascular events resulting in exercise termination. Wearable devices will be used to identify exercise episodes and analyze dynamic physiological characteristics during exercise and recov
Time frame: From the date of baseline enrollment until the date of first exercise-related cardiovascular event or censoring, assessed up to 12 months.
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers to protect participant privacy and confidentiality, in compliance with local ethical and data governance requirements.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.
Of 345 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 31 months is below that.
Counting every sponsor, half of 426 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital →